Key result
Anesthetic preconditioning decreased myocardial infarct size compared with control (26% vs 46%, P<0.05), an effect blocked by hyperglycemia but restored by the BH4 precursor sepiapterin.
Why the study?
Does sepiapterin restore anesthetic preconditioning-induced cardioprotection during hyperglycemia in preclinical models?
Does sepiapterin restore anesthetic preconditioning-induced cardioprotection during hyperglycemia in preclinical models?
Absolute Event Rate: 26% vs 46%
p-value: p=<0.05
Enhancing the production of BH4 with sepiapterin restores the cardioprotective effects of anesthetic preconditioning that are otherwise abolished by hyperglycemia.
May support BH4-targeted strategies to preserve anesthetic preconditioning in hyperglycemia; hypothesis-generating and requires clinical translation studies.
BACKGROUND: Endothelial nitric oxide synthase activity is regulated by (6R-)5,6,7,8-tetrahydrobiopterin (BH4) and heat shock protein 90. The authors tested the hypothesis that hyperglycemia abolishes anesthetic preconditioning (APC) through BH4- and heat shock protein 90-dependent pathways. METHODS: Myocardial infarct size was measured in rabbits in the absence or presence of APC (30 min of isoflurane), with or without hyperglycemia, and in the presence or absence of the BH4 precursor sepiapterin. Isoflurane-dependent nitric oxide production was measured (ozone chemiluminescence) in human coronary artery endothelial cells cultured in normal (5.5 mm) or high (20 mm) glucose conditions, with or without sepiapterin (10 or 100 microm). RESULTS: APC decreased myocardial infarct size compared with control experiments (26 +/- 6% vs. 46 +/- 3%, respectively; P < 0.05), and this action was blocked by hyperglycemia (43 +/- 4%). Sepiapterin alone had no effect on infarct size (46 +/- 3%) but restored APC during hyperglycemia (21 +/- 3%). The beneficial actions of sepiapterin to restore APC were blocked by the nitric oxide synthase inhibitor N (G)-nitro-L-arginine methyl ester (47 +/- 2%) and the BH4 synthesis inhibitor N-acetylserotonin (46 +/- 3%). Isoflurane increased nitric oxide production to 177 +/- 13% of baseline, and this action was attenuated by high glucose concentrations (125 +/- 6%). Isoflurane increased, whereas high glucose attenuated intracellular BH4/7,8-dihydrobiopterin (BH2) (high performance liquid chromatography), heat shock protein 90-endothelial nitric oxide synthase colocalization (confocal microscopy) and endothelial nitric oxide synthase activation (immunoblotting). Sepiapterin increased BH4/BH2 and dose-dependently restored nitric oxide production during hyperglycemic conditions (149 +/- 12% and 175 +/- 9%; 10 and 100 microm, respectively). CONCLUSION: The results indicate that tetrahydrobiopterin and heat shock protein 90-regulated endothelial nitric oxide synthase activity play a central role in cardioprotection that is favorably modulated by volatile anesthetics and dysregulated by hyperglycemia. Enhancing the production of BH4 may represent a potential therapeutic strategy.
No takes yet. Share an insight, caveat, or question.
Amour et al. (2010) studied Myocardial infarction and hyperglycemia. Anesthetic preconditioning (isoflurane) and sepiapterin vs. Control experiments was evaluated on Myocardial infarct size (p=<0.05). Anesthetic preconditioning decreased myocardial infarct size compared with control (26% vs 46%, P<0.05), an effect blocked by hyperglycemia but restored by the BH4 precursor sepiapterin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: